Home » Newsletters » BioWorld Science

BioWorld Science

March 19, 2015

View Archived Issues

ODYSSEY studies demonstrate greater LDL cholesterol reductions for alirocumab over placebo

New NIAID grant supports Inovio's collaborative HIV program

NantWorks and Sorrento Therapeutics establish new cancer immunotherapy collaboration

The Icahn School of Medicine at Mount Sinai presents Brd4 inhibitors

Cloud Pharmaceuticals and University of Florida collaborate on MTH1 inhibitors for cancer

Esperion's phase IIb study of ETC-1002 in hypercholesterolemia meets primary endpoint

Melphalan flufenamide receives U.S. orphan drug status for multiple myeloma

Aldeyra Therapeutics opens enrollment in Sjogren-Larsson syndrome trial

Pharmalink acquires osteoarthritis candidate from Synartro

Coherus finalizes CHS-1701 BLA-enabling program and begins pivotal PK study

Ezetimibe/simvastatin combination improves clinical efficacy in ACS patients

NovImmune's HLH trial of NI-0501 allows first-line treatment after protocol amendment

FDA approves Cholbam for rare bile acid synthesis disorders

Novogen reports on potential of Anisina to become new chemotherapy

Hsa-miRNA-181c shows potential as a new diagnostic marker for ACLF

Astellas submits supplemental NDA for Kiklin in Japan

Hanmi Pharmaceutical launches phase II trial of HM-61713

Collagen-targeted nanoparticles containing Ac2-26 peptide provide insight into atherosclerosis

Emergent manufactures MVA EBOZ Ebola vaccine candidate under new agreements

Prexa Pharmaceuticals patents monoamine transporter ligands

Kyoto Pharmaceutical develops novel aromatic compounds

French researchers report development of MMP inhibitors

Chinese researchers report mTOR and PI3Kalpha inhibitors

FDA extends Kalydeco approval to younger children with cystic fibrosis

AstraZeneca and Daiichi Sankyo sign U.S. co-commercialization agreement for Movantik

Case report of emergency postexposure vaccination with VSVdeltaG-ZEBOV

Allena reports phase IIa data on ALLN-177 for the treatment of hyperoxaluria

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...